Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot cuts migraine days by half in chinese trial

NCT ID NCT05458011

Disease control Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called fremanezumab, given as a shot under the skin, to prevent migraines in 365 Chinese adults. Participants received either monthly or quarterly injections or a placebo for 12 weeks, followed by an open-label period. The main goal was to see if the drug reduced the number of migraine days per month. The trial was completed and showed that fremanezumab helped lower migraine frequency.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

365 people

The number who actually took part.

Started

Sep 2022

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant has a diagnosis of migraine with onset at ≤50 years of age. * The participant has a body weight ≥45 kg and body mass index within the range 17.5 to 34.9 kg/m2 (inclusive). * The participant has a history of migraine for ≥12 months prior to screening. * Women of childbearing potential (WOCBP) whose male partners are potentially fertile (that is; no vasectomy) must use highly effective birth control methods for the duration of the study and for 6.0 months after discontinuation of investigational medicinal product (IMP). * Men must be sterile or, if they are potentially fertile/reproductively competent (not congenitally sterile) and their female partners are of childbearing potential, should use highly effective birth control for the duration of the study. * Additional criteria apply, please contact the investigator for more information. Exclusion Criteria: * Use of medications containing opioids (including codeine), barbiturates (including butalbital), or any combination product containing opioids or barbiturates (including butalbital) on more than 4 days during the screening period for the treatment of migraine or for any other reason. * Has used an intervention/device (eg, scheduled nerve blocks or transcranial magnetic stimulation) for migraine, or in the head or neck area, during the 2 months prior to screening (visit 1). * History of clinically significant cardiovascular disease or vascular ischemia (such as myocardial, neurological \[eg, cerebral ischemia\], or peripheral extremity ischemia or other ischemic event) or thromboembolic events (arterial or venous thrombotic or embolic events), such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism. * History of human immunodeficiency virus, tuberculosis, Lyme disease, or a known or suspected active infection of coronavirus disease 2019 (COVID-19). * Known current infection or history of infection in the past 6 months with hepatitis B or C viruses. * History of cancer in the past 5 years, except for appropriately treated non-melanoma skin carcinoma. * History of hypersensitivity reactions to injected proteins, including monoclonal antibodies (mAbs), or a history of Stevens-Johnson Syndrome or toxic epidermal necrolysis syndrome, or is concomitantly using lamotrigine. * Any clinically significant uncontrolled medical condition (treated or untreated). * History of alcohol or drug abuse during the past 2 years or drug dependence during the past 5 years. * Additional criteria apply, please contact the investigator for more information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • Teva Investigational Site 88001

    Beijing, 100853, China

  • Teva Investigational Site 88003

    Chengdu, 610041, China

  • Teva Investigational Site 88004

    Beijing, 100044, China

  • Teva Investigational Site 88005

    Luoyang, 4710039, China

  • Teva Investigational Site 88006

    Wuhan, 430071, China

  • Teva Investigational Site 88008

    Changchun, 130021, China

  • Teva Investigational Site 88009

    Changchun, 130041, China

  • Teva Investigational Site 88010

    Lianyungang, 222002, China

  • Teva Investigational Site 88011

    Shijiazhuang, 50073, China

  • Teva Investigational Site 88012

    Wuhan, 430030, China

  • Teva Investigational Site 88013

    Guiyang, 550004, China

  • Teva Investigational Site 88015

    Suzhou, 215004, China

  • Teva Investigational Site 88016

    Shenyang, 110016, China

  • Teva Investigational Site 88017

    Wenzhou, 325000, China

  • Teva Investigational Site 88019

    Fuzhou, 350001, China

  • Teva Investigational Site 88020

    Guangzhou, 510260, China

  • Teva Investigational Site 88021

    Shanghaishi, 200040, China

  • Teva Investigational Site 88022

    Changsha Shi, 410008, China

  • Teva Investigational Site 88023

    Tianjin, 300120, China

  • Teva Investigational Site 88024

    Tianjin, 300052, China

  • Teva Investigational Site 88025

    Shanghaishi, 200120, China

  • Teva Investigational Site 88026

    Harbin, 150001, China

  • Teva Investigational Site 88028

    Baotou Shi, 014060, China

  • Teva Investigational Site 88029

    Chongqing, 400700, China

  • Teva Investigational Site 88030

    Changsha Shi, 410013, China

  • Teva Investigational Site 88031

    Zhanjiang, 524008, China

  • Teva Investigational Site 88032

    Xining, 810007, China

  • Teva Investigational Site 88033

    Rizhao, 276800, China

  • Teva Investigational Site 88034

    Zhengzhou, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.